Big firms showcase promising pipeline assets at ASCO 2023

6 June 2023

As the final sessions of the 2023 congress of the American Society of Clinical Oncology (ASCO) draw to a close, attendees will reflect on a number of significant presentations, from both smaller biotechs and large drugmakers.

One closely-watched area of research is TIGIT inhibition, with Gilead Sciences (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) updating the congress on progress from its ARC-7 study of TIGIT blocker domvanalimab, together with the checkpoint blocker zimberelimab.

While the interim analysis in that presentation failed to show a significant improvement from an earlier update, Roche’s (ROG: SIX) TIGIT blocker tiragolumab appears to hold more promise.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK